151 related articles for article (PubMed ID: 27939985)
1. Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
Xu W; Lu C; Yao L; Zhang F; Shao J; Zheng S
Toxicol Appl Pharmacol; 2017 Jan; 315():23-34. PubMed ID: 27939985
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin attenuates alcoholic fatty liver through regulation of lipin-1 signaling.
Chen X; Bian M; Jin H; Lian N; Shao J; Zhang F; Zheng S
IUBMB Life; 2019 Nov; 71(11):1740-1750. PubMed ID: 31265202
[TBL] [Abstract][Full Text] [Related]
3. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
[TBL] [Abstract][Full Text] [Related]
4. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
[TBL] [Abstract][Full Text] [Related]
5. Bruceine A alleviates alcoholic liver disease by inhibiting AIM2 inflammasome activation via activating FXR.
Li L; Xu S; Wang W; Li X; Wang H; Yang Q; Wang C; Gu J; Luo H; Meng Q
Phytomedicine; 2024 Jul; 130():155693. PubMed ID: 38763006
[TBL] [Abstract][Full Text] [Related]
6. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
[TBL] [Abstract][Full Text] [Related]
7. Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes.
Lu C; Zhang F; Xu W; Wu X; Lian N; Jin H; Chen Q; Chen L; Shao J; Wu L; Lu Y; Zheng S
IUBMB Life; 2015 Aug; 67(8):645-58. PubMed ID: 26305715
[TBL] [Abstract][Full Text] [Related]
8. FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease.
Li L; Kong L; Xu S; Wang C; Gu J; Luo H; Meng Q
Hepatol Int; 2024 Feb; 18(1):188-205. PubMed ID: 38183609
[TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin inhibits ER stress-mediated mitochondrial pathway to attenuate hepatocyte lipoapoptosis via blocking the activation of the PI3K/Akt pathway.
Chen X; Bian M; Zhang C; Kai J; Yao Z; Jin H; Lu C; Shao J; Chen A; Zhang F; Zheng S
Biomed Pharmacother; 2018 Jan; 97():975-984. PubMed ID: 29136776
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism.
Xu W; Lu C; Zhang F; Shao J; Zheng S
IUBMB Life; 2016 May; 68(5):376-87. PubMed ID: 27027402
[TBL] [Abstract][Full Text] [Related]
11. Yangonin inhibits ethanol-induced hepatocyte senescence via miR-194/FXR axis.
Dong R; Wang X; Wang L; Wang C; Huang K; Fu T; Liu K; Wu J; Sun H; Meng Q
Eur J Pharmacol; 2021 Jan; 890():173653. PubMed ID: 33068587
[TBL] [Abstract][Full Text] [Related]
12. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity.
Manley S; Ni HM; Williams JA; Kong B; DiTacchio L; Guo G; Ding WX
Redox Biol; 2014; 2():991-1002. PubMed ID: 25460735
[TBL] [Abstract][Full Text] [Related]
14. Ligustrazine prevents alcohol-induced liver injury by attenuating hepatic steatosis and oxidative stress.
Lu C; Xu W; Zhang F; Jin H; Chen Q; Chen L; Shao J; Wu L; Lu Y; Zheng S
Int Immunopharmacol; 2015 Dec; 29(2):613-621. PubMed ID: 26459052
[TBL] [Abstract][Full Text] [Related]
15. Altered ethanol metabolism and increased oxidative stress enhance alcohol-associated liver injury in farnesoid X receptor-deficient mice.
Morel C; Chowdhary V; Thevkar Nagesh P; Ribeiro M; Hawryluk D; Catalano D; Adorini L; Szabo G
Liver Int; 2023 Jan; 43(1):100-114. PubMed ID: 35869657
[TBL] [Abstract][Full Text] [Related]
16. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
17. Relevance of FXR-p62/SQSTM1 pathway for survival and protection of mouse hepatocytes and liver, especially with steatosis.
Haga S; Yimin ; Ozaki M
BMC Gastroenterol; 2017 Jan; 17(1):9. PubMed ID: 28086800
[TBL] [Abstract][Full Text] [Related]
18. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
Meng Q; Duan XP; Wang CY; Liu ZH; Sun PY; Huo XK; Sun HJ; Peng JY; Liu KX
Acta Pharmacol Sin; 2017 Jan; 38(1):69-79. PubMed ID: 27773935
[TBL] [Abstract][Full Text] [Related]
19. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
20. Yangonin protects against estrogen-induced cholestasis in a farnesoid X receptor-dependent manner.
Dong R; Wang J; Gao X; Wang C; Liu K; Wu J; Liu Z; Sun H; Ma X; Meng Q
Eur J Pharmacol; 2019 Aug; 857():172461. PubMed ID: 31220436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
